KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash from Financing Activities (2017 - 2025)

Twist Bioscience (TWST) has disclosed Cash from Financing Activities for 9 consecutive years, with $298000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 98.34% to $298000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.9 million through Dec 2025, down 58.59% year-over-year, with the annual reading at $28.5 million for FY2025, 314.22% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $298000.0 at Twist Bioscience, down from $5.6 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $271.6 million in Q1 2022, with the low at -$1.5 million in Q4 2023.
  • Average Cash from Financing Activities over 5 years is $15.5 million, with a median of $1.5 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities skyrocketed 18619.23% in 2022, then crashed 272.91% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$1.0 million in 2021, then surged by 60.93% to -$395000.0 in 2022, then plummeted by 272.91% to -$1.5 million in 2023, then surged by 1318.19% to $17.9 million in 2024, then plummeted by 98.34% to $298000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $298000.0, $5.6 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.